Condition: Androgenetic Alopecia (AGA) · Androgenetic Alopecia · AGA · Sponsor: Veradermics, Inc.
This study will evaluate the safety and efficacy of VDPHL01 in female subjects with Androgenetic Alopecia (AGA). AGA is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormones) that causes hair loss. VDPHL01 is an investigational oral drug to treat AGA. This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6, month 8, month 10, month 12, month 13).
This description comes directly from the study's public registry record.
AGA Study Manager · 858-571-1800 · clinicalresearch@therapeuticsinc.com
Always discuss trial participation with your own doctor first.
| Site 73 | Birmingham, Alabama, United States | Recruiting |
| Site 89 | Birmingham, Alabama, United States | Recruiting |
| Site 77 | Phoenix, Arizona, United States | Recruiting |
| Site 30 | Fort Smith, Arkansas, United States | Recruiting |
| Site 69 | Encino, California, United States | Recruiting |
| Site 2 | Fremont, California, United States | Recruiting |
| Site 64 | Manhattan Beach, California, United States | Recruiting |
| Site 93 | Northridge, California, United States | Recruiting |
| Site 66 | Santa Monica, California, United States | Recruiting |
| Site 34 | Sherman Oaks, California, United States | Recruiting |
| Site 94 | Thousand Oaks, California, United States | Recruiting |
| Site 21 | Vista, California, United States | Recruiting |
+ 59 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07146022